April 2, 2019
Reviewed By: 

Atezolizumab (Tecentriq) is an immunotherapyinfo-icon approved by the Food and Drug Administrationinfo-icon to treat metastaticinfo-icon triple-negative breast cancerinfo-icon that expresses the PD-L1 proteininfo-icon. Immunotherapies push the body's own immune systeminfo-icon to attack cancer cells. Atezolizumab is the first immunotherapy to show positive results in in phase III trialinfo-icon for triple-negative breast cancer.

Atezolizumab works in people who have tumors that express the PD-L1 protein. This protein has a role in telling the immune system that a given cellinfo-icon is part of your body. In tumors that express PD-L1, the protein tricks the immune system into believing cancer cells are healthy cells, which prevents these cells from attacking the cancer.

Atezolizumab blocks PD-L1, allowing the immune system to attack breast cancer cells.

Atezolizumab is only approved for people with triple-negative breast cancer and is given with the chemotherapyinfo-icon nab-paclitaxelinfo-icon.

How Atezolizumab Works

An immunotherapyinfo-icon is a medicineinfo-icon that works to engage your immune systeminfo-icon, your body's natural defense against diseases. Since cancer cells are mutated versions of your own cells, the immune system treats them as a natural part of your body. Immunotherapies block certain communications between immune cells and cancer cells. This causes the immune system to treat the cancer cells as a threat and to destroy them.

Atezolizumab targets the PD-L1 proteininfo-icon, stopping a reaction that tells immune cells not to attack breast cancer cells. With that reaction blocked, the immune system sees breast cancer cells as a disease and destroys them.

The PD-L1 protein is not found in all tumors. Doctors will test the immune cells in and around the breast cancer to see if they express PD-L1 and are likely to respond to atezolizumab.

How Atezolizumab is Given

Atezolizumab is given by veininfo-icon at your treatment center. The first treatment is given over the course of an hour, and follow-up infusions are given every 3 weeks and take 30 minutes.

Side Effects and Things to Remember

People taking atezolizumab and nab-paclitaxelinfo-icon experienced side effects including nauseainfo-icon, cough, low white blood cellinfo-icon counts and hypothyroidism, a conditioninfo-icon where your body does not produce enough thyroid hormones. People taking atezolizumab are also more likely to experience gradeinfo-icon 3 or 4 neuropathyinfo-icon than people taking nab-paclitaxel alone. Side effects that are grade 3 or 4 interfere with daily life and require medical attention.

Atezolizumab, like other immunotherapies, is linked to immune-related side effects that can take different forms, including problems in the lungs, liver or intestines or reactions to the infusioninfo-icon of the medicineinfo-icon. Your healthcare providers will talk to you about watching for these problems and what symptoms you should report right away.

You must have Javascript enabled to use this form.

More In Immunotherapy